8-K: Supernus Pharmaceuticals Holds Annual Meeting, Votes Cast

Supernus Pharmaceuticals, Inc. reported the results of its annual meeting of stockholders held on June 18, 2026, detailing votes on director elections, executive compensation, auditor ratification, and equity incentive plan amendments.

Summary

• Supernus Pharmaceuticals, Inc. held its annual meeting of stockholders on June 18, 2026.
• The meeting included votes on the election of Class I Directors, approval of executive compensation, ratification of KPMG LLP as the independent auditor, and an amendment to the 2021 Equity Incentive Plan.
• As of April 29, 2026, there were 58,039,721 shares of common stock outstanding and eligible to vote.
• Directors Frederick M. Hudson and Charles W. Newhall, III were elected.
• The compensation paid to named executive officers was approved on a non-binding basis.
• KPMG LLP was ratified as the independent public accounting firm for the fiscal year ending December 31, 2026.
• A proposal to amend the 2021 Equity Incentive Plan to increase the number of available shares was also voted upon.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive filing, reflecting routine corporate governance activities with generally expected outcomes, though the dissent on executive compensation warrants attention.

Positives

• Directors Frederick M. Hudson and Charles W. Newhall, III were elected with significant majority votes.
• The appointment of KPMG LLP as the independent public accounting firm for fiscal year 2026 was ratified with overwhelming support.
• The proposal to amend the 2021 Equity Incentive Plan to increase available shares received substantial approval.

Negatives

• A notable number of broker non-votes (3,073,181) were recorded for the director elections and the equity incentive plan amendment.
• While approved non-binding, the compensation paid to named executive officers received a significant number of votes against (1,675,355).

Risks

• The significant number of votes against executive compensation could signal potential shareholder dissatisfaction with pay practices.
• Broker non-votes for director elections and equity plan amendments might indicate a lack of engagement from a portion of the shareholder base or specific voting instructions from beneficial owners.

Future Outlook

The filing does not contain specific forward-looking statements or guidance beyond the election of directors to serve until the 2029 annual meeting and the ratification of the auditor for the 2026 fiscal year.

Management Comments

• Timothy C. Dec, Senior Vice President and Chief Financial Officer, signed the report, indicating executive oversight of the filing.
• The company held its annual meeting of stockholders, a routine event for corporate governance and shareholder engagement.

Industry Context

StockSavvy.ai notes that the results of annual meetings, particularly votes on director elections and executive compensation, are closely watched by investors as indicators of corporate governance and management alignment with shareholder interests within the pharmaceutical sector.

Corporate Governance

Stakeholder Impact

• Shareholders: Voting outcomes directly impact board composition and executive compensation oversight. The equity plan amendment affects future share dilution.
• Management: The vote on executive compensation provides direct feedback on their pay structure.
• Employees: The approved equity incentive plan amendment will allow for continued stock-based compensation.

Next Steps

• Class I Directors Frederick M. Hudson and Charles W. Newhall, III will serve until the Annual Meeting of the Company in 2029.
• KPMG LLP will serve as the independent public accounting firm for the fiscal year ending December 31, 2026.
• The Supernus Pharmaceuticals, Inc. 2021 Equity Incentive Plan will be amended to increase the number of shares available.

Key Dates

Recommendation

The filing reports on routine annual meeting matters with generally expected outcomes. While the election of directors and auditor ratification were strongly supported, the significant dissent on executive compensation and the number of broker non-votes suggest a need for further monitoring rather than a strong buy or sell signal.

Keywords

Supernus Pharmaceuticals, 8-K, Annual Meeting, Stockholder Vote, Director Election, Executive Compensation, KPMG LLP, Equity Incentive Plan